PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Aeglea BioTherapeutics, Inc. (AGLE)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS00773J1034
CUSIP00773J103
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$48.63M
EPS-$74.15
PE Ratio11.17
Revenue (TTM)$1.05M
Gross Profit (TTM)-$262.00K
EBITDA (TTM)-$98.84M
Year Range$2.66 - $28.66
Target Price$17.50
Short %3.47%
Short Ratio3.68

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Aeglea BioTherapeutics, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Aeglea BioTherapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%100.00%150.00%Nov 26Dec 03Dec 10Dec 17Dec 24Dec 31Jan 07Jan 14Jan 21Jan 28
-88.70%
141.19%
AGLE (Aeglea BioTherapeutics, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period


PeriodReturnBenchmark
Year-To-DateN/A11.56%
1 monthN/A7.13%
6 monthsN/A17.26%
1 yearN/A26.92%
5 years (annualized)N/A13.56%
10 years (annualized)N/A10.87%

Monthly Returns

The table below presents the monthly returns of AGLE, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202311.14%-21.60%-26.02%-41.83%-23.00%246.81%25.44%1.75%-14.78%-4.98%60.31%15.33%91.33%
2022-9.47%-35.58%-16.97%-37.39%9.72%-68.03%-17.76%25.90%0.57%95.82%-59.71%8.41%-90.53%
2021-11.69%7.19%6.31%-1.77%-15.04%5.30%-11.93%18.27%9.66%-7.92%-14.75%-23.88%-39.64%
2020-4.97%-5.92%-31.77%66.74%13.38%4.99%-25.95%6.20%-2.54%8.32%11.46%-8.06%3.01%
201922.03%-8.53%-3.71%-14.91%-8.91%9.78%30.80%-12.89%-1.47%-1.04%12.35%-10.64%2.00%
201819.78%11.88%36.83%-5.85%14.35%-0.94%-20.51%29.96%-12.44%-9.82%-2.43%-11.05%38.45%
2017-8.28%55.39%20.16%-4.03%-40.98%-8.77%-11.43%20.53%19.94%-11.15%-8.68%35.25%24.37%
2016-10.34%-14.38%-35.20%-1.23%17.50%13.65%-16.38%-3.54%-15.86%-55.48%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Aeglea BioTherapeutics, Inc. (AGLE) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


AGLE
Sharpe ratio
No data
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.34, compared to the broader market-2.00-1.000.001.002.003.004.002.34
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.31, compared to the broader market-4.00-2.000.002.004.006.003.31
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.41, compared to the broader market0.501.001.502.001.41
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.90, compared to the broader market0.002.004.006.001.90
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 8.93, compared to the broader market-10.000.0010.0020.0030.008.93

Sharpe Ratio

There is not enough data available to calculate the Sharpe ratio for Aeglea BioTherapeutics, Inc.. We calculate this metric based on the past 12 months of trading data. Please check back later for updated information.


Rolling 12-month Sharpe Ratio0.000.501.001.502.00Nov 26Dec 03Dec 10Dec 17Dec 24Dec 31Jan 07Jan 14Jan 21Jan 28
0.34
1.67
AGLE (Aeglea BioTherapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Aeglea BioTherapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%Nov 26Dec 03Dec 10Dec 17Dec 24Dec 31Jan 07Jan 14Jan 21Jan 28
-90.79%
-0.06%
AGLE (Aeglea BioTherapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Aeglea BioTherapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Aeglea BioTherapeutics, Inc. was 99.11%, occurring on Jun 21, 2023. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.11%Apr 11, 20161812Jun 21, 2023

Volatility

Volatility Chart

The current Aeglea BioTherapeutics, Inc. volatility is 23.43%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%Nov 26Dec 03Dec 10Dec 17Dec 24Dec 31Jan 07Jan 14Jan 21Jan 28
23.43%
2.68%
AGLE (Aeglea BioTherapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Aeglea BioTherapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items